What factors affect a sufficient dose of ivermectin?

Ivermectin is a semi -synthetic antihelmintic or antiparasitic agent sold under the Stromectol® brand. Ivermectin is closely related to other members of the avermectin drug class, it is effective against a wide range of parasites. It has been approved for use in the treatment of onchocemerciasis, ascariasis, singloidiasis, skin larvae migrans, scabies and filariasis. Ivermektin is also approved in the case of philaiosis in pediatric populations, although a lower dose of ivermectin should be used. In addition to the patient's age, other common factors that affect the recommended initial dose of ivermectin, reduced liver function, reduced immune system activity, and the type of parasitic condition to be treated.

In the treatment of onchocericiasis, one oral dose is usually required only once a year, although patients with severe eye infections may require treatment every three to six months. A dose of ivermectin 3 MGND £ 55 (15 and 25 kg) should be used in patients with body weight. Patients weighing between 57.2 and96.8 pounds (£ 26 and 44) ​​should be given double dose, while patients between £ 99 and £ 140.8 (£ 45 and 64) should receive a dose of 9 mg of ivermectin. Patients between 143 and 184.8 pounds (65 and 84 kg) should have a dose of 12 mg, while heavier patients should be given 0.15 mg to £ 2.2 (1 kg) body weight.

In rare cases, some patients with onChocericiasis - both with or without treatment - developed a potentially fatal state of the brain characterized by red eye, back and neck pain, breathing problems, loss of urine and intestinal control, bleeding eyes, loss or coordination, seizures. Some patients strongly infected LOA - commonly referred to as "eye worm" - can also experience fatal encephalopathy. Because Ivermectin itself is not an effective means of removing adults to be onchocerca parasite, retreating or surgical excision.

in the treatment of ascariasis, leatherThe larvae of the migrans, scabies or philarosis, one dose of 0.2 mg to £ 2.2 (1 kg) of body weight should suffice. In the treatment of persistent infections of philarosis, the annual dose of 0.4 mg per 2.2 pounds (1 kg) of body weight, along with a dose of diethylcarbamazine at 6 mg per 2.2 pound (1 kg), showed the weight effective. Treatment of sakia infections may require administration of two or more doses of ivermectin each one or two weeks.

Since the chemical is strongly metabolized in the liver, it is likely that lower doses may be necessary in patients with reduced liver function. Since 2011, no studies have been conducted to determine the appropriate dose of ivermectin in populations with compromised liver function, so that this drug should be used with caution in patients with liver disease. Similarly, the research of this drug did not include the high -rise of a geriatric sample. Although it is possible that lower doses may be preferred in patients over 65 years, the relevant dose of ivermectin must still be determined.